Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
medrxiv; 2021.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2021.10.18.21265128

ABSTRACT

Background: Previous results from observational, interventional studies and in vitro experiments suggest that certain micronutrients have anti-viral and immunomodulatory activities. In particular, it has been hypothesized that zinc, selenium, copper and vitamin K1 have strong potential for prophylaxis and treatment of COVID-19. Objectives: We aimed to test whether genetically predicted Zn, Se, Cu or vitamin K1 levels have a causal effect on COVID-19 related outcomes: risk of infection, hospitalization and critical illness. Methods: We employed two-sample Mendelian Randomization (MR) analysis. Our genetic variants derived from European-ancestry GWAS reflected circulating levels of Zn, Cu, Se in red blood cells as well as Se and vitamin K1 in serum/plasma. For the COVID-19 outcome GWAS, we used infection, hospitalization or critical illness. Our inverse-variance weighted (IVW) MR analysis was complemented by sensitivity analyses: more liberal selection of variants at genome-wide subsignificant threshold, MR-Egger and weighted median/mode tests. Results: Circulating micronutrient levels show limited evidence of association with COVID-19 infection with odds ratio [OR] ranging from 0.97 (95% CI: 0.87-1.08, p-value=0.55) for zinc to 1.07 (95% CI: 1.00-1.14, p-value=0.06) - ie. no beneficial effect for copper, per 1 SD increase in exposure. Similarly minimal evidence was obtained for the hospitalization and critical illness outcomes with OR from 0.98 (95% CI: 0.87-1.09, p-value=0.66) for vitamin K1 to 1.07 (95% CI: 0.88-1.29, p-value=0.49) for copper, and from 0.93 (95% CI: 0.72-1.19, p-value=0.55) for vitamin K1 to 1.21 (95% CI: 0.79-1.86, p-value=0.39) for zinc, respectively. Conclusions: This study does not provide evidence that supplementation with zinc, selenium, copper or vitamin K1 can prevent SARS-CoV-2 infection, critical illness or hospitalization for COVID-19.


Subject(s)
COVID-19 , Critical Illness
SELECTION OF CITATIONS
SEARCH DETAIL